NCT03547245View on ClinicalTrials.gov

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

January 17, 2020

Study Completion Date

August 13, 2021

Conditions
HIV/AIDS
Interventions
BIOLOGICAL

eOD-GT8 60mer + AS01B/ DPBS sucrose/IM

20 μg

BIOLOGICAL

eOD-GT8 60mer + AS01B/ DPBS sucrose/IM

100 μg

BIOLOGICAL

DPBS Sucrose

Placebo

Trial Locations (2)

20037

George Washington University, Washington D.C.

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
lead

International AIDS Vaccine Initiative

NETWORK

NCT03547245 - A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted | Biotech Hunter | Biotech Hunter